Incannex Completes Dosing in Psilocybin Anxiety Study
    Incannex Completes Dosing in Psilocybin Anxiety Study
    PRISM Biotech

    Incannex Completes Dosing in Psilocybin Anxiety Study

    25 January 2024

    New York, January 25, 2024 - PrismMarketView - Incannex Healthcare (Nasdaq: IXHL) has completed dosing of 72 participants in a Phase 2 clinical study evaluating a psilocybin treatment program for patients with generalized anxiety disorder (GAD). Incannex is preparing an Investigational New Drug (IND) application and will submit to the FDA following receipt of topline results from this clinical trial.

    Incannex Healthcare Limited - Prism MarketView

    Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine th

    Read More

    Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences - Prism MarketView

    Incannex HealthcareHighlights:72 patients treated at purpose-built facilities within Monash University, Melbourne, Australia.Topline results from the trial anticipated within current Q1 2024.FDA IND application is well-advanced...

    Read More

    “We’re delighted to have completed all PsiGAD-1 treatments for our trial participants as we work towards finalizing an FDA IND application to advance the development of this important treatment modality. Generalized anxiety disorder is characterized by persistent, debilitating and excessive worry, affects millions of people globally, and has inadequate existing treatment options. We’re thankful to our research partners at Monash University who conducted a thorough and extensive clinical trial, screening 975 people and undertaking 174 psychedelic dosing sessions in one of the largest clinical trials of its kind.”

    Joel Latham, Chief Executive Officer and Director of Incannex

    Highlights
    Incannex’s study is a randomized triple-blind active-placebo-controlled Phase 2 trial. The primary objective of the study is to determine whether a 7-week program of psilocybin-assisted psychotherapy for GAD is superior to active placebo-assisted psychotherapy in decreasing symptoms of GAD.
    The study also assessed safety, as well as other secondary objectives of efficacy and quality of life.
    In March of 2023, Incannex announced the interim analysis for the Phase 2 PsiGAD-1 clinical trial, which predicted a greater than 85% chance that the trial would show statically significant benefit for the psilocybin treatment arm versus the placebo arm at the conclusion of the trial period.
    About Incannex Healthcare Inc.
    Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.
    U.S. FDA approval and registration, subject to ongoing clinical success, is being pursued for each drug and therapy under development. Each indication under investigation currently has no, or limited, existing registered pharmacotherapy (drug) treatments available to the public and represent major global economic opportunities to Incannex and its shareholders.
    Incannex has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. The Company holds 20 granted patents and over 30 pending patent applications.
    PRISM MarketView does not provide investment advice.
    Media Contact
    Company Name: Prism MarketView
    Email: info@prismmarketview.com
    Phone: 646-863-6341
    Website: https://prismmarketview.com
    To see this content properly accept cookies.
    PRISM MarketView Social Media
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.